Replies to post #390461 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

I don't think that is the issue.

It is not primarily NWBO's executive team or others handling the analysis but more likely UCLA/Dr. Liau and others who are reviewing on the clinical teams from trial centers, so I don't think that will be or is the likely problem. They have lots of other experts advising as well, including likely members of the SAB.